⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10957642 | 0.97 | HSD17B10 (0.38) | — | |
| SCHEMBL327328 | 0.92 | CA2 (0.43) | — | |
| SCHEMBL15500216 | 0.90 | CA2 (0.47) | — | |
| SCHEMBL4101877 | 0.90 | CA2 (0.47) | — | |
| SCHEMBL6691473 | 0.90 | CA2 (0.47) | — | |
| SCHEMBL6687367 | 0.88 | CA2 (0.45) | — | |
| SCHEMBL27617655 | 0.88 | CA2 (0.45) | — | |
| SCHEMBL11340050 | 0.88 | CA2 (0.45) | — | |
| SCHEMBL11333558 | 0.88 | CA2 (0.45) | — | |
| SCHEMBL742169 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116042505-A | Pinus massoniana embryogenic cell culture medium and cell maturation culture method | 广西壮族自治区林业科学研究院 | 2023-05-02 | — | — | CN | disclosed |
| US-20180074079-A1 | COMPOSITIONS AND METHODS TO ASSESS THE CAPACITY OF HDL TO SUPPORT REVERSE CHOLESTEROL TRANSPORT | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2018-03-15 | — | — | US | disclosed |
| US-20160305967-A1 | COMPOSITIONS AND METHODS TO ASSESS THE CAPACITY OF HDL TO SUPPORT REVERSE CHOLESTEROL TRANSPORT | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND | 2016-10-20 | — | — | US | disclosed |
| US-20140162376-A1 | COMPOSITIONS AND METHODS TO ASSESS THE CAPACITY OF HDL TO SUPPORT REVERSE CHOLESTEROL TRANSPORT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-06-12 | — | — | US | disclosed |
| EP-2708529-A1 | METHOD FOR MANUFACTURING PARTICLES | Sumitomo Chemical Company Limited (JP) | 2014-03-19 | — | — | EP | disclosed |
| EP-2702400-A2 | COMPOSITIONS AND METHODS TO ASSESS THE CAPACITY OF HDL TO SUPPORT REVERSE CHOLESTEROL TRANSPORT | Children's Hospital & Research Center at Oakland (US) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012149473-A2 | COMPOSITIONS AND METHODS TO ASSESS THE CAPACITY OF HDL TO SUPPORT REVERSE CHOLESTEROL TRANSPORT | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2008037827-A1 | USE OF PARTICULAR ANTIBACTERIAL COMPOUNDS, WHICH ARE DERIVED FROM ALLIACEAE, AS NATURAL ADDITIVES IN ANIMAL FEED | DMC RESEARCH CENTER, S.L. (ES) | 2008-04-03 | — | — | WO | disclosed |
| CN-1493561-A | Preparation of substituted pyridine N-oxide compound | DSM精细化学奥地利NFG两合公司 | 2004-05-05 | — | — | CN | disclosed |
| WO-1992016213-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| WO-1992016233-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| US-4111697-A | NOVEL ANTIFOGGING AND/OR STABILIZING COMPOUNDS FOR SILVER HALIDE PHOTOGRAPHY | AGFA-GEVAERT, N. V. (BE) | 1978-09-05 | — | — | US | disclosed |